Olverembatinib

Olverembatinib (GZD824, HQP1351) is an orally bioavailable inhibitor of pan-Bcr-Abl. It effectively inhibits a wide range of Bcr-Abl mutants, with IC50 of 0.34 nM and 0.68 nM for native Bcr-Abl and the Bcr-AblT315I mutant, respectively. It also induces tumor regression in mouse xenograft models.